Combination chemotherapy with doxorubicin, vincristine, cyclophosphamide, and platinum compounds for advanced thymic carcinoma.

@article{Agatsuma2011CombinationCW,
  title={Combination chemotherapy with doxorubicin, vincristine, cyclophosphamide, and platinum compounds for advanced thymic carcinoma.},
  author={Toshihiko Agatsuma and Tomonobu Koizumi and Shintaro Kanda and Michiko Ito and Kazuhisa Urushihata and Hiroshi Yamamoto and Masayuki Hanaoka and Keishi Kubo},
  journal={Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer},
  year={2011},
  volume={6 12},
  pages={2130-4}
}
INTRODUCTION Thymic carcinoma is a rare epithelial neoplasm that tends to be aggressive and metastasize widely. The optimal chemotherapy for unresectable advanced thymic carcinoma has not yet been established because of its rare occurrence. The purpose of this study was to evaluate the efficacy and tolerability of combination chemotherapy with doxorubicin, vincristine, cyclophosphamide, and platinum compounds for advanced thymic carcinoma. METHODS A retrospective analysis of 34 patients with… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 1 time. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 20 extracted citations

Are Anthracycline-Based Regimens Truly Indicated To Be the Standard Chemotherapy Regimen for Thymic Carcinoma?

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer • 2016

A Prospective Phase II Study of Cisplatin and Cremophor EL-Free Paclitaxel (Genexol-PM) in Patients with Unresectable Thymic Epithelial Tumors.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer • 2015

Similar Papers

Loading similar papers…